Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

REHOVOT, Israel, July 8, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company utilizing cutting-edge artificial intelligence and predictive biology to drive innovation in life-science product development, today announced the successful completion and closing of…

Speciality chemicals manufacturer ICL buys Lavie Bio activity from Evogene in latest deal for ag biologicals

Computational biology company Evogene has officially completed its sale of “the majority of” subsidiary Lavie Bio‘s activity to Israel-based speciality chemicals manufacturer ICL. The deal was first announced in April of this year. Lavie Bio, which uses computational biology to speed up the discovery and development ag biological products, had previously struck an agreement with ICL in 2024 to co-develop novel biostimulant products. (It has also…